Inhibrx Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-241.36	-145.23	-81.77	-76.12	-51.4	-31.16
Depreciation & Amortization	2.96	2.85	2.69	2.39	2.52	0.68
Share-Based Compensation	24.85	20.45	15.05	5.02	3.97	2.48
Other Operating Activities	20.25	6.63	-16.29	20.74	12.83	4.91
Operating Cash Flow	-193.31	-115.3	-80.32	-47.97	-32.08	-23.09
Capital Expenditures	-4.59	-0.69	-0.81	-1.36	-1.81	-1.43
Investing Cash Flow	-4.59	-0.69	-0.81	-1.36	-1.81	-1.43
Share Issuance / Repurchase	201.96	130.13	44.16	136.88	0	0
Debt Issued / Paid	0	128.81	39.99	40.57	33.81	-5.69
Other Financing Activities	-	-0.39	-0.38	-10.99	9.52	18.84
Financing Cash Flow	201.96	258.55	83.77	166.46	43.33	13.15
Net Cash Flow	4.06	142.56	2.64	117.12	9.44	-11.37
Free Cash Flow	-197.9	-115.99	-81.13	-49.33	-33.89	-24.52
Free Cash Flow Margin	-10994.56%	-5291.38%	-1122.00%	-382.77%	-256.52%	-285.29%
Free Cash Flow Per Share	-4.20	-2.89	-2.13	-1.95	-1.87	-1.35

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).